{"id":118512,"date":"2025-10-29T15:13:00","date_gmt":"2025-10-29T18:13:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/"},"modified":"2025-10-29T15:13:00","modified_gmt":"2025-10-29T18:13:00","slug":"circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/","title":{"rendered":"Circle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation"},"content":{"rendered":"

CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) — Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in cardiovascular imaging solutions, today announced that its cvi42 \/ Plaque solution has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available for clinical use in the United States. This innovative, AI-enabled solution allows clinicians to perform comprehensive coronary plaque analysis directly on-premise, enhancing diagnostic workflows and patient care.<\/p>\n

The clearance of cvi42 \/ Plaque marks a significant advancement for cardiology departments and imaging centers, stated Erkan Akyuz, CEO of Circle CVI. As a secure, on-premise solution, it allows for the evaluation of coronary artery disease without the need to send patient data to an external reading service. This provides clinicians with greater control over their data, improved study processing times, and enhanced workflow efficiency.<\/p>\n

The AI-enabled technology within cvi42 \/ Plaque delivers fast, accurate, and reproducible results for quantifying total, calcified, and non-calcified plaque. This detailed analysis supports more precise risk stratification and helps inform personalized treatment plans.<\/p>\n

With the new cvi42 \/ Plaque, I now have immediate and interactive control over my anatomic coronary CCTA imaging analysis, said Dr. James Thompson, DO, Director of Adult Congenital Heart Disease at Johns Hopkins. Circle CVI truly comes full circle continuing to invest, innovate, and impress by advancing imaging applications and enhancing our cardiac CTA workflow. This is foundational to CCTAs front-line role in cardiovascular disease prevention, driving early translational impact and transformative patient care. Empowering early detection of the high-risk plaque attack.<\/p>\n

Medicare now covers AI-enabled coronary plaque analysis from CCTA with a Category III CPT code, 0625T, and national payment set at $950 under recent policy updates, alongside higher base payments for the underlying CCTA exam. With cvi42 \/ Plaque, cardiac imaging sites can retain most of the reimbursement, rather than outsourcing analysis and reimbursement to external providers.<\/p>\n

AI-enabled coronary plaque analysis has been assigned a permanent Category I CPT code, 75XX6, which takes effect in January 2026. This new code, replacing previous Category III codes, facilitates national pricing and enables physician reimbursement; the AMAs update signifies that plaque quantification is now recognized as standard clinical care in cardiovascular medicine.<\/p>\n

cvi42 \/ Plaque integrates seamlessly into existing CT workflows and is compatible with all major vendor systems, providing a complete solution for cardiac imaging teams. The FDA clearance reinforces Circle CVI’s commitment to delivering innovative, reliable, and user-friendly solutions that empower clinicians to provide the best possible care for their patients.<\/p>\n

David Wilson
david.wilson@circlecvi.com<\/a> <\/p>\n

A video accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/940e82f4-e7c0-4852-b34f-4dfb569a02c2<\/a><\/p>\n

<\/p>\n

\"\"
\"\"
\n\"Primary<\/a><\/p>\n

A OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP<\/b> e sao de inteira responsabilidade da GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) — Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in cardiovascular imaging solutions, today announced","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-118512","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"yoast_head":"\nCircle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation - Ag\u00eancia de Comunica\u00e7\u00e3o<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Circle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation - Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"og:description\" content=\"CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in cardiovascular imaging solutions, today announced\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/\" \/>\n<meta property=\"og:site_name\" content=\"Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T18:13:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=\" \/>\n<meta name=\"author\" content=\"patric_oliveira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"patric_oliveira\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/\"},\"author\":{\"name\":\"patric_oliveira\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"headline\":\"Circle CVI Announces FDA Clearance for cvi42 \\\/ Plaque for Coronary Artery Disease Evaluation\",\"datePublished\":\"2025-10-29T18:13:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/\"},\"wordCount\":491,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=\",\"articleSection\":[\"Releases Geral\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/\",\"name\":\"Circle CVI Announces FDA Clearance for cvi42 \\\/ Plaque for Coronary Artery Disease Evaluation - Ag\u00eancia de Comunica\u00e7\u00e3o\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=\",\"datePublished\":\"2025-10-29T18:13:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/releases\\\/releases-geral\\\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Circle CVI Announces FDA Clearance for cvi42 \\\/ Plaque for Coronary Artery Disease Evaluation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\",\"name\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"description\":\"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\",\"name\":\"patric_oliveira\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"caption\":\"patric_oliveira\"},\"sameAs\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"],\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/author\\\/patric_oliveira\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Circle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation - Ag\u00eancia de Comunica\u00e7\u00e3o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/","og_locale":"pt_BR","og_type":"article","og_title":"Circle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation - Ag\u00eancia de Comunica\u00e7\u00e3o","og_description":"CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Circle Cardiovascular Imaging Inc. (Circle CVI), a global leader in cardiovascular imaging solutions, today announced","og_url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/","og_site_name":"Ag\u00eancia de Comunica\u00e7\u00e3o","article_published_time":"2025-10-29T18:13:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=","type":"","width":"","height":""}],"author":"patric_oliveira","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"patric_oliveira","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#article","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/"},"author":{"name":"patric_oliveira","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"headline":"Circle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation","datePublished":"2025-10-29T18:13:00+00:00","mainEntityOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/"},"wordCount":491,"commentCount":0,"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=","articleSection":["Releases Geral"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/","name":"Circle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation - Ag\u00eancia de Comunica\u00e7\u00e3o","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#primaryimage"},"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=","datePublished":"2025-10-29T18:13:00+00:00","author":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"breadcrumb":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NDY0NyM3MjMyNDk1IzIzMDY3MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/circle-cvi-announces-fda-clearance-for-cvi42-plaque-for-coronary-artery-disease-evaluation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"},{"@type":"ListItem","position":2,"name":"Circle CVI Announces FDA Clearance for cvi42 \/ Plaque for Coronary Artery Disease Evaluation"}]},{"@type":"WebSite","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/","name":"Ag\u00eancia de Comunica\u00e7\u00e3o","description":"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37","name":"patric_oliveira","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","caption":"patric_oliveira"},"sameAs":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"],"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/author\/patric_oliveira\/"}]}},"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/118512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=118512"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/118512\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=118512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=118512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=118512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}